Press Releases

June 17, 2010

FDA approves Tasigna® for newly diagnosed chronic myeloid leukemia patients, data demonstrate major advance over Gleevec®

May 28, 2009

Data on more than 15 Novartis Oncology compounds at ASCO highlight progress toward targeted therapies for diverse tumor types

 

March 30, 2009

Afinitor® approved in US as first treatment for patients with advanced kidney cancer after failure of either sunitinib or sorafenib

 

January 13, 2009

RAD001 Phase II trial results positive in patients with advanced gastric cancer after failure of one or more prior treatments

 

January 13, 2009

New study first to confirm Sandostatin LAR® Depot controls tumor growth in patients with rare gastrointestinal tumors

December 12, 2008

RAD001 shows potential to reverse resistance to Herceptin®* in metastatic breast cancer patients, leading to Phase III trial

 

September 16, 2008

Latest RAD001 study results show further increase in time without tumor growth in patients with advanced kidney cancer

 

September 13, 2008

RAD001 combined with Sandostatin LAR® Depot and as monotherapy controls growth of rare pancreatic neuroendocrine tumors

 

September 9, 2008

RAD001 Granted Priority Review in the US Based on Potential to Fill Unmet Medical Need in Patients With Advanced Kidney Cancer

 

August 27, 2008

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

 

June 13, 2008

Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia

 

June 2, 2008

Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments

 

May 31, 2008

Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer

 

May 19, 2008

RAD001 more than doubles time without tumor growth after failure of standard treatment in patients with advanced kidney cancer

 

May 14, 2008

Strength and innovation of Novartis Oncology products and pipeline with potential to improve patient treatment demonstrated by more than 170 abstracts at ASCO annual meeting

 

March 10, 2008

Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy

 

February 28, 2008

Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy

The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on Novartis' website for historical purposes only. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.